GSK Puts Up (Another) Venture Fund

The name of GlaxoSmithKline's just-launched, $500 million venture fund--GSK Venture Fund--lacks pizzazz, but might do more for the pharma firm on a broader scale than its precursor, SR One. The new effort, which has yet to be formally announced, takes a more conventional--and maybe more assertive--VC approach to nailing down rights and/or starting product- and technology-focused companies.